論文・総説 - 永田　哲也

分割表示  109 件中 1 - 20 件目  ／  全件表示 >>

  1. Matsubayashi T, Yoshioka K, Lei Mon SS, Katsuyama M, Jia C, Yamaguchi T, Hara RI, Nagata T, Nakagawa O, Obika S, Yokota T. Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4'-BNA/LNA with 9-(aminoethoxy)phenoxazine. Molecular therapy. Nucleic acids. 2024.06; 35 (2): 102161. ( PubMed, DOI )

  2. Sano T, Nagata T, Ebihara S, Yoshida-Tanaka K, Nakamura A, Sasaki A, Shimozawa A, Mochizuki H, Uchihara T, Hasegawa M, Yokota T. Effects of local reduction of endogenous α-synuclein using antisense oligonucleotides on the fibril-induced propagation of pathology through the neural network in wild-type mice. Acta neuropathologica communications. 2024.05; 12 (1): 75. ( PubMed, DOI )

  3. Yum J, Aulia F, Kamiya K, Hori M, Qiao N, Kim BS, Naito M, Ogura S, Nagata T, Yokota T, Uchida S, Obika S, Kim HJ, Miyata K. Hydrophobicity Tuning of Cationic Polyaspartamide Derivatives for Enhanced Antisense Oligonucleotide Delivery. Bioconjugate chemistry. 2024.02; 35 (2): 125-131. ( PubMed, DOI )

  4. Watanabe N, Tone Y, Nagata T, Masuda S, Saito T, Motohashi N, Takagaki K, Aoki Y, Takeda S. Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide. Molecular therapy. Nucleic acids. 2023.12; 34 102034. ( PubMed, DOI )

  5. Yanagidaira M, Yoshioka K, Nagata T, Nakao S, Miyata K, Yokota T. Effects of combinations of gapmer antisense oligonucleotides on the target reduction. Molecular biology reports. 2023.04; 50 (4): 3539-3546. ( PubMed, DOI )

  6. Li F, Ichinose K, Ishibashi S, Yamamoto S, Iwasawa E, Suzuki M, Yoshida-Tanaka K, Yoshioka K, Nagata T, Hirabayashi H, Mogushi K, Yokota T. Preferential delivery of lipid-ligand conjugated DNA/RNA heteroduplex oligonucleotide to ischemic brain in hyperacute stage. Molecular therapy : the journal of the American Society of Gene Therapy. 2023.04; 31 (4): 1106-1122. ( PubMed, DOI )

  7. Jia C, Lei Mon SS, Yang Y, Katsuyama M, Yoshida-Tanaka K, Nagata T, Yoshioka K, Yokota T. Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route. Molecular therapy. Nucleic acids. 2023.03; 31 182-196. ( PubMed, DOI )

  8. Amano A, Sanjo N, Araki W, Anraku Y, Nakakido M, Matsubara E, Tomiyama T, Nagata T, Tsumoto K, Kataoka K, Yokota T. Peripheral administration of nanomicelle-encapsulated anti-Aβ oligomer fragment antibody reduces various toxic Aβ species in the brain. Journal of nanobiotechnology. 2023.01; 21 (1): 36. ( PubMed, DOI )

  9. Goto A, Yamamoto S, Igari T, Matsumoto SI, Chisaki I, Iida K, Nakayama M, Oda A, Kakoi Y, Uchida A, Miyata K, Nishikawa M, Nagata T, Kusuhara H, Yokota T, Hirabayashi H. Quantitative Model Analysis and Simulation of Pharmacokinetics and Metastasis-Associated Lung Adenocarcinoma 1 RNA Knockdown Effect After Systemic Administration of Cholesterol-Conjugated DNA/RNA Heteroduplex Oligonucleotide Crossing Blood-Brain Barrier of Mice. The Journal of pharmacology and experimental therapeutics. 2023.01; 384 (1): 197-204. ( PubMed, DOI )

  10. Nishi R, Ohyagi M, Nagata T, Mabuchi Y, Yokota T. Regulation of activated microglia and macrophages by systemically administered DNA/RNA heteroduplex oligonucleotides. Molecular therapy : the journal of the American Society of Gene Therapy. 2022.06; 30 (6): 2210-2223. ( PubMed, DOI )

  11. Miyashita A, Kobayashi M, Ishibashi S, Nagata T, Chandrasekhar A, Zochodne DW, Yokota T. The Role of Long Noncoding RNA MALAT1 in Diabetic Polyneuropathy and the Impact of Its Silencing in the Dorsal Root Ganglion by a DNA/RNA Heteroduplex Oligonucleotide. Diabetes. 2022.06; 71 (6): 1299-1312. ( PubMed, DOI )

  12. Kaburagi H, Nagata T, Enomoto M, Hirai T, Ohyagi M, Ihara K, Yoshida-Tanaka K, Ebihara S, Asada K, Yokoyama H, Okawa A, Yokota T. Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve. Molecular therapy. Nucleic acids. 2022.06; 28 910-919. ( PubMed, DOI )

  13. Nagata T, Dwyer CA, Yoshida-Tanaka K, Ihara K, Ohyagi M, Kaburagi H, Miyata H, Ebihara S, Yoshioka K, Ishii T, Miyata K, Miyata K, Powers B, Igari T, Yamamoto S, Arimura N, Hirabayashi H, Uchihara T, Hara RI, Wada T, Bennett CF, Seth PP, Rigo F, Yokota T. Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS. Nature biotechnology. 2021.12; 39 (12): 1529-1536. ( PubMed, DOI )

  14. Ohyagi M, Nagata T, Ihara K, Yoshida-Tanaka K, Nishi R, Miyata H, Abe A, Mabuchi Y, Akazawa C, Yokota T. DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo. Nature communications. 2021.12; 12 (1): 7344. ( PubMed, DOI )

  15. Motohiro Suzuki, Satoru Ishibashi, Eri Iwasawa , Takahiro Oguma, Yasuhiro Saito, Fuying Li, Shinichi Otsu, Keiko Ichinose, Kotaro Yoshioka, Tetsuya Nagata, Takanori Yokota. Effective silencing of miR-126 after ischemic stroke by means of intravenous α-tocopherol-conjugated heteroduplex oligonucleotide in mice. Scientific reports. 2021.07; 11 (1): 14237. ( PubMed, DOI )

  16. Asada K, Sakaue F, Nagata T, Zhang JC, Yoshida-Tanaka K, Abe A, Nawa M, Nishina K, Yokota T. Short DNA/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencing. Nucleic acids research. 2021.05; 49 (9): 4864-4876. ( PubMed, DOI )

  17. Ono D, Asada K, Yui D, Sakaue F, Yoshioka K, Nagata T, Yokota T. Separation-related rapid nuclear transport of DNA/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking. Molecular therapy. Nucleic acids. 2021.03; 23 1360-1370. ( PubMed, DOI )

  18. Yutaro Asami, Tetsuya Nagata, Kotaro Yoshioka, Taiki Kunieda, Kie Yoshida-Tanaka, C Frank Bennett, Punit P Seth, Takanori Yokota. Efficient Gene Suppression by DNA/DNA Double-Stranded Oligonucleotide In Vivo. Molecular therapy : the journal of the American Society of Gene Therapy. 2021.02; 29 (2): 838-847. ( PubMed, DOI )

  19. Yuki Kishimoto, Osamu Nakagawa, Akane Fujii, Kotaro Yoshioka, Tetsuya Nagata, Takanori Yokota, Yoshiyuki Hari, Satoshi Obika. 2',4'-BNA/LNA with 9-(2-Aminoethoxy)-1,3-diaza-2-oxophenoxazine Efficiently Forms Duplexes and Has Enhanced Enzymatic Resistance*. Chemistry (Weinheim an der Bergstrasse, Germany). 2021.02; 27 (7): 2427-2438. ( PubMed, DOI )

  20. Naito M, Chaya H, Toh K, Kim BS, Hayashi K, Fukushima S, Nagata T, Yokota T, Kataoka K, Miyata K. Structural tuning of oligonucleotides for enhanced blood circulation properties of unit polyion complexes prepared from two-branched poly(ethylene glycol)-block-poly(l-lysine). Journal of controlled release : official journal of the Controlled Release Society. 2021.02; 330 812-820. ( PubMed, DOI )

< 前のページ - 次のページ >

このページの先頭へ▲